Skip to content
lifestyle.social-matic.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ipsen Pharma
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
May 24, 2026
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
May 23, 2026
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
February 12, 2026
←
Previous Page
1
2